NCT03697265 - A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD) | Biotech Hunter

Enrollment

475

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

July 28, 2020

Study Completion Date

October 23, 2020

Conditions

Premenstrual Dysphoric Disorder

Interventions

DRUG

Sepranolone (UC1010) low dose

Subcutaneous (SC) administration

DRUG

Sepranolone (UC1010) high dose

Subcutaneous (SC) administration

DRUG

Placebo

Subcutaneous (SC) adminstration

Trial Locations (12)

Karolinska University Hospital, Stockholm

Zentrum für Klinische Forschnung, Bad Homburg

Emovis, Berlin

Medizentrum Essen Borbeck, Essen

Klinische Forschung Karlsruhe GmbH, Karlsruhe

Praxis Dr. Steinwachs, Nuremberg

Centrum Kliniczno-Badawcze, Elblag

Centrum Medyczne Angelius Provita, Katowice

ProCreative, Krakow

Liverpool Women's NHS Foundation Trust, Liverpool

Imperial College London, London

Obstetrics and Gynaecology Keele University School of Medicine and University Hospitals of North Staffordshire, Stoke-on-Trent